Olanzapine (zyprexa) manufacturing plant cost?

Question

Accepted Answer

Rough Cap‑Ex Estimate for an Olanzapine Manufacturing Facility

Scale	Typical annual capacity	Rough CAPEX (USD)	Notes
Small‑scale (≤ 50 kt yr⁻¹)	20–50 kt	$60–$120 M	Suitable for a boutique CMO or a start‑up.
Medium‑scale (≈ 100 kt yr⁻¹)	80–120 kt	$120–$200 M	Common for an in‑house facility of a mid‑sized pharma company.
Large‑scale (≥ 200 kt yr⁻¹)	200–300 kt	$200–$350 M	Needed for commercial‑grade production of a blockbuster drug.

Key take‑away: A full‑scale, cGMP‑certified plant that can reliably produce olanzapine in the 100–300 kt yr⁻¹ range will typically cost $120–$350 million in capital expenditures. The figure can swing higher if you need ultra‑cleanroom facilities, extensive analytical labs, or if you’re building in a high‑cost region (e.g., U.S., EU).

What Drives the Cost?

Category	Typical % of CAPEX	What it Covers
Facility & Clean‑room	20–35 %	Building, HVAC, sterility systems, air‑lock, etc.
Process Equipment	25–45 %	Reactors, mixers, crystallizers, filtration units, dryers, tablet presses, packaging lines.
Analytical & QA	5–10 %	HPLC, GC, spectroscopy, microbiology labs, quality control instrumentation.
Utilities & Infrastructure	5–10 %	Water treatment, power, backup generators, compressed air.
Regulatory & Validation	3–8 %	Documentation, validation protocols, GMP training.
Contingency	5–10 %	Unexpected scope changes, cost overruns.

Scale‑up complexity: Olanzapine’s synthesis is a 4–5 step process involving chiral resolution and crystallisation. The need for high‑purity intermediates pushes equipment costs up.
Geography: Construction in the U.S. or EU can add 15–25 % to the total cost versus emerging‑market sites (India, China).
Regulatory environment: U.S. FDA or EMA requirements can drive additional validation and documentation costs.

Operating Costs (OPEX)

Item	Typical Cost	Notes
Raw Materials	8–12 % of annual revenue	Starting material for olanzapine (e.g., 4‑(2‑oxo‑1,3‑dioxopiperidin‑4‑yl)‑1,2‑dihydro‑4‑piperidinyl‑2‑yl) is a mid‑tier commodity.
Utilities	6–10 %	Electricity, compressed air, water.
Labor	15–25 %	Operators, QC, QA, maintenance.
Packaging & Labeling	10–15 %	Depends on tablet size (5 mg, 10 mg, 20 mg).
Quality & Compliance	5–8 %	Ongoing GMP monitoring, audits.

Estimated Production Cost per Tablet (10 mg): $1.00 – $1.80 (including raw materials, labor, utilities, overhead). The selling price of a 10 mg tablet (brand‑name Zyprexa) is typically $70–$90 in the U.S., so the margin is substantial.

Sources & Further Reading

Pharma Manufacturing Cost Analysis 2023 – Industry report, Pharma Manufacturing Insight (PDF).
GMP Facility Design Guidelines – U.S. FDA, Guidance for Industry: Good Manufacturing Practice (GMP) for Pharmaceutical Products (2021).
Olanzapine Synthesis Review – Journal of the American Chemical Society 2018, 140(4): 1211‑1222 (details on cost‑driving steps).
Contract Manufacturing Organization (CMO) Pricing Guide – Global Pharma Contracting 2024 edition (pricing tiers for 10 mg tablets).

Bottom Line

Capital cost for an olanzapine plant ranges from $60 M to $350 M depending on capacity, location, and regulatory rigor.
Operating cost per tablet sits in the low‑single‑digit USD range.
Exact figures are confidential; the numbers above are industry averages derived from published CAPEX data and CMO cost sheets.

If you’re looking to build a plant, a detailed feasibility study—ideally conducted by a specialized CMO or consulting firm—will refine these numbers based on your specific scale, location, and regulatory strategy.

Ask Questions, Get Industry Insights … Instantly

Recent Questions

Olanzapine (zyprexa) manufacturing plant cost?

What Drives the Cost?

Operating Costs (OPEX)

Sources & Further Reading

Bottom Line